Postprandial Lipid Metabolism in Patients With Hypertriglyceridemia and Normo-lipidemic Controls: Medium Chain Fatty Acids (MCT) in Comparison to Long-chain, Saturated Fatty Acids (SFA) and Mono-unsaturated Fatty Acids (MUFA)
Not Applicable
Completed
- Conditions
- Hypertriglyceridemia
- Registration Number
- NCT03846908
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Brief Summary
Postprandial lipid metabolism will be evaluated in patients with hypertriglyceridemia and normo-lipidemic controls; different fats will be used (saturated fatty acids, mon-unsaturated fatty acids and medium chain fatty acids) for the oral fat challenge.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
- hypertriglyceridemia (150 mg/dl-900 mg/dl)
Exclusion Criteria
- Lipid lowering drugs or indication for Lipid lowering drugs
- LDL-cholesterol > 190 mg/dl
- Diabetes mellitus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method postprandial hypertriglyceridemia 8 hours after fat meal area under the curve following oral fat load
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MCT-induced lipid metabolism changes in hypertriglyceridemia patients compared to SFA and MUFA?
How does MCT intervention compare to standard-of-care treatments in managing postprandial hypertriglyceridemia?
Which biomarkers correlate with differential postprandial lipid responses to MCT, SFA, and MUFA in hypertriglyceridemia?
What adverse events are associated with MCT consumption in hypertriglyceridemic individuals versus normo-lipidemic controls?
Are there synergistic effects when combining MCT with fibrates or omega-3 fatty acids in lipid metabolism disorders?
Trial Locations
- Locations (1)
University Munich
🇩🇪Munich, Germany
University Munich🇩🇪Munich, Germany